| Yi-zarn Wang, MD | |
|
701 W 5th St, Odessa, TX 79763-4206 | |
| (432) 335-2222 | |
| (432) 335-1693 |
| Full Name | Yi-zarn Wang |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 701 W 5th St, Odessa, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295826774 | NPI | - | NPPES |
| 1995606 | Medicaid | LA | |
| 05334356 | Medicaid | MS |
| Entity Name | Louisiana State University School Of Medicine In New Orleans Faculty G |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477582526 PECOS PAC ID: 0244136448 Enrollment ID: O20031209000661 |
News Archive
Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.
A recent study showed that people who drink tea regularly have brains which function better and also show a greater degree of organization. This could strengthen the case for drinking tea to help prevent dementia. The study is important because, unlike most others which look only at tests of mental ability, it also examined structural brain changes with tea drinking.
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
Neogenix Oncology, Inc., announced today that they were awarded "Emerging Company of the Year" by The Tech Council of Maryland, the state's largest technology trade association at its 22nd Annual Tech Awards including more than 800 technology and business leaders from around the region.
DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yi-zarn Wang, MD 701 W 5th St, Odessa, TX 79763-4206 Ph: (432) 335-2222 | Yi-zarn Wang, MD 701 W 5th St, Odessa, TX 79763-4206 Ph: (432) 335-2222 |
News Archive
Whether a stem cell transplant using an HIV-infected person's own genetically modified immune cells can become a cure for the disease is the focus of a new $20 million, five-year research grant award announced today by the National Institutes of Health to Fred Hutchinson Cancer Research Center.
A recent study showed that people who drink tea regularly have brains which function better and also show a greater degree of organization. This could strengthen the case for drinking tea to help prevent dementia. The study is important because, unlike most others which look only at tests of mental ability, it also examined structural brain changes with tea drinking.
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
Neogenix Oncology, Inc., announced today that they were awarded "Emerging Company of the Year" by The Tech Council of Maryland, the state's largest technology trade association at its 22nd Annual Tech Awards including more than 800 technology and business leaders from around the region.
DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.
› Verified 3 days ago
Dr. Nathaniel Wolkenfeld, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 540 W 5th St Ste 470, Odessa, TX 79761 Phone: 432-580-8330 | |
Dr. Katherine Jenson, MD Surgery Medicare: Medicare Enrolled Practice Location: 500 W 4th St, Odessa, TX 79761 Phone: 432-640-4000 | |
Dr. Noel Feliciano Villanueva, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 850 Tower Dr Ste 111, Odessa, TX 79761 Phone: 432-580-7440 Fax: 432-580-7730 | |
Dr. Shai Yuan Liu, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 318 N Alleghaney Ave, Ste 301, Odessa, TX 79761 Phone: 432-333-2878 Fax: 432-333-2882 | |
Subhash K Nagalla, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 420 E 6th St Ste 102, Odessa, TX 79761 Phone: 432-888-9001 Fax: 324-888-9002 | |
Jofrances Armeza Marquez Jr., MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 408 N Hancock Ave, Odessa, TX 79761 Phone: 432-580-7373 |